Loading...
XSTO
MCOVb
Market cap3.23bUSD
Apr 15, Last price  
209.00SEK
1D
1.70%
1Q
4.92%
IPO
227.84%
Name

Medicover AB

Chart & Performance

D1W1MN
P/E
171.03
P/S
1.37
EPS
0.11
Div Yield, %
0.67%
Shrs. gr., 5y
2.41%
Rev. gr., 5y
19.89%
Revenues
2.09b
+19.78%
365,300,000415,600,000497,300,000580,200,000671,600,000844,400,000997,800,0001,377,400,0001,510,200,0001,746,400,0002,091,800,000
Net income
17m
-5.11%
4,300,0007,500,0004,300,00018,700,00024,600,00022,500,00025,800,000101,800,00011,800,00017,600,00016,700,000
CFO
262m
+27.76%
21,700,00028,700,00025,900,00050,300,00044,400,00087,300,000156,000,000216,700,000170,200,000205,000,000261,900,000
Dividend
Apr 30, 20250 SEK/sh
Earnings
Apr 24, 2025

Profile

Medicover AB (publ) provides healthcare and diagnostic services in Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. It operates through two segment, Healthcare Services and Diagnostic Services. The company's diagnostic services comprise various tests, including allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology. The company operates 97 clinical laboratories, 733 blood-drawing points, and 26 clinics in 10 countries; and 117 medical clinics, 20 fertility clinics, 52 dental clinics, 25 hospitals, and 25 gyms. It serves corporate and private customers, and patients, as well as public payers. Medicover AB (publ) was founded in 1995 and is headquartered in Stockholm, Sweden.
URL
https://www.medicover.com/
IPO date
May 23, 2017
Employees
44,000
Domiciled in
SE
Incorporated in
SE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,091,800
19.78%
1,746,400
15.64%
1,510,200
9.64%
Cost of revenue
2,021,500
1,689,700
1,243,100
Unusual Expense (Income)
NOPBT
70,300
56,700
267,100
NOPBT Margin
3.36%
3.25%
17.69%
Operating Taxes
5,500
5,200
5,800
Tax Rate
7.82%
9.17%
2.17%
NOPAT
64,800
51,500
261,300
Net income
16,700
-5.11%
17,600
49.15%
11,800
-88.41%
Dividends
(18,000)
(17,900)
(17,800)
Dividend yield
0.06%
0.08%
0.09%
Proceeds from repurchase of equity
(300)
BB yield
0.00%
Debt
Debt current
258,300
229,100
101,900
Long-term debt
1,497,700
1,213,400
1,262,400
Deferred revenue
Other long-term liabilities
67,100
137,800
87,200
Net debt
1,668,700
1,372,400
1,305,600
Cash flow
Cash from operating activities
261,900
205,000
170,200
CAPEX
(122,300)
(110,500)
(140,600)
Cash from investing activities
(134,700)
(119,800)
(184,800)
Cash from financing activities
(108,000)
(73,700)
(24,300)
FCF
(45,800)
(10,300)
70,700
Balance
Cash
82,800
64,400
49,100
Long term investments
4,500
5,700
9,600
Excess cash
Stockholders' equity
128,700
191,000
193,700
Invested Capital
1,795,300
1,669,800
1,512,500
ROIC
3.74%
3.24%
18.30%
ROCE
3.84%
3.40%
17.18%
EV
Common stock shares outstanding
150,197
149,652
148,717
Price
192.00
27.91%
150.10
7.44%
139.70
-62.24%
Market cap
28,837,804
28.38%
22,462,821
8.12%
20,775,809
-62.15%
EV
30,531,004
23,987,421
22,258,409
EBITDA
284,900
239,100
429,000
EV/EBITDA
107.16
100.32
51.88
Interest
58,800
51,400
34,500
Interest/NOPBT
83.64%
90.65%
12.92%